Three Relay Therapeutics executives sold shares totaling over $82,000 on July 30, 2026. The selling group included the Chief Financial Officer and the President of Research and Development.
Relay Therapeutics will report its second-quarter 2026 financial results on August 6. Investors expect this report to provide clinical updates on the lead drug candidate, zovegalisib.
Analysts recently raised price expectations based on confidence in the company's oncology pipeline. However, the insider activity introduces a note of caution ahead of the upcoming financial and clinical milestones.